Skip to main content
. Author manuscript; available in PMC: 2018 Jul 15.
Published in final edited form as: Clin Cancer Res. 2017 Nov 8;24(2):360–369. doi: 10.1158/1078-0432.CCR-17-1606

Figure 6. Venetoclax disrupts BIM:BCL-2 complexes in vivo in the LU5263 PDX model.

Figure 6

(A) Induction of the apoptosis marker cleaved PARP (cPARP) in three control and three, 3-day venetoclax treated LU5263 tumors. GAPDH was used as a loading control. (B) Tumor lysates from 3-day venetoclax treated LU5263 tumors were immunoprecipitated using an anti-BIM antibody. Western blot analysis was carried out on precipitated and input samples using the antibodies indicated.